Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 1;3(9):e2017517.
doi: 10.1001/jamanetworkopen.2020.17517.

Trends in Primary Treatment and Median Survival Among Women With Advanced-Stage Epithelial Ovarian Cancer in the US From 2004 to 2016

Anne T Knisely  1 , Caryn M St Clair  1 , June Y Hou  1 , Fady Khoury Collado  1 , Dawn L Hershman  2 , Jason D Wright  1 , Alexander Melamed  1
Affiliations

Trends in Primary Treatment and Median Survival Among Women With Advanced-Stage Epithelial Ovarian Cancer in the US From 2004 to 2016

Anne T Knisely et al. JAMA Netw Open. .

Abstract

This cohort study compares time trends in the use of neoadjuvant chemotherapy and survival rates among women with advanced-stage epithelial ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Wright reported receiving personal fees from Clovis Oncology and research funding from Merck outside the submitted work. Dr Hou reported serving as a consultant for Foundation Medicine. No other disclosures were reported.

Figures

Figure.
Figure.. Time Trends in Use of Primary Chemotherapy and Median Survival in Commission on Cancer–accredited Cancer Centers in the United States
Whiskers indicate 95% CIs; dashed vertical lines, year when statistically significant changes of trend in the use of neoadjuvant chemotherapy were identified by join point models; and solid lines, predictions from join point models.
See this image and copyright information in PMC

References

    1. Vergote I, Tropé CG, Amant F, et al. ; European Organization for Research and Treatment of Cancer—Gynaecological Cancer Group; NCIC Clinical Trials Group . Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943-953. doi:10.1056/NEJMoa0908806 - DOI - PubMed
    1. Kehoe S, Hook J, Nankivell M, et al. . Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249-257. doi:10.1016/S0140-6736(14)62223-6 - DOI - PubMed
    1. Onda T, Satoh T, Ogawa G, et al. ; Japan Clinical Oncology Group . Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial. Eur J Cancer. 2020;130:114-125. doi:10.1016/j.ejca.2020.02.020 - DOI - PubMed
    1. Huelsmann E, Zighelboim I, Ahmed A, Dewdney S. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists, a 5-year follow-up. Gynecol Oncol Rep. 2017;20:47-50. doi:10.1016/j.gore.2017.02.005 - DOI - PMC - PubMed
    1. Melamed A, Hinchcliff EM, Clemmer JT, et al. . Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States. Gynecol Oncol. 2016;143(2):236-240. doi:10.1016/j.ygyno.2016.09.002 - DOI - PubMed

Publication types

MeSH terms

Substances